topic

1258 Clinical and demographic factors associated with immune related adverse events among those treated with immune checkpoint inhibitors
Savannah C Roy, Junxiao Hu, S Lindsey Davis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1393; DOI: 10.1136/jitc-2023-SITC2023.1258
1259 Comparison of blinatumomab and biosimilar CD19xCD3 BiTE responses in PBMC-humanized mice used as a preclinical lymphoma mouse model
Ilian Radichev, Jiwon Yang, Won Lee, Destanie Rose, James G Keck

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1394; DOI: 10.1136/jitc-2023-SITC2023.1259
1260 Rapid cytokine release syndrome caused by short-term CAR T cells in a preclinical mouse model
Arezoo Jamali, Naphang Ho, Angela Braun, Elham Adabi, Frederic B Thalheimer, Christian J Buchholz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1395; DOI: 10.1136/jitc-2023-SITC2023.1260
1261 Patterns of dermatological and other immune related adverse events as a signal for survival
John Hunting, Eric Olson, Ruth Sacks, Andrew Faucheux, Tom Lycan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1396; DOI: 10.1136/jitc-2023-SITC2023.1261
1262 Immune checkpoint inhibitor-induced inflammatory arthritis is associated with cutaneous, endocrine, and gastrointestinal immune-related adverse events: a machine learning approach
Steven Tran, Jean Lin, Carlos Galvez, Luke V Rasmussen, Jennifer Pacheco, Giovanni M Perottino, Kian J Rahbari, Charles D Miller, Jordan D John, Jonathan Theros, Kelly Vogel, Patrick V Dinh, Sara Malik, Umar Ramzan, Kyle Tegtmeyer, Nisha Mohindra, Yuan Luo, Abel Kho, Jeffrey Sosman, Theresa L Walunas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1397-A1398; DOI: 10.1136/jitc-2023-SITC2023.1262
1263 Characterizing steroid-refractory immunotherapy toxicities and effect of second-line immunosuppression on clinical outcomes
Michelle Ferreira, Jennifer Guo, Tyler Jones, Steven Wolf, Christy Arrowood, Donna Niedzwiecki, Brent A Hanks

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1399; DOI: 10.1136/jitc-2023-SITC2023.1263
1264 Recognition and management of immunotherapy toxicity: a quality improvement project
Shree Spandana Ghanta, Kavya Nalluri, Oluwatayo Adeoye, Olga Kozyreva

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1400; DOI: 10.1136/jitc-2023-SITC2023.1264
1265 Single-institution retrospective review of patient’s diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
Antonious Hazim, Damian McGlothlin, Gordon Ruan, Irene Riestra Guiance, Keith Mcconn, Jacob Shreve, Robert Haemmerle, Konstantinos Leventakos, Ashley Egan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1401; DOI: 10.1136/jitc-2023-SITC2023.1265
1266 Utilizing predictive modeling to risk stratify patients to low versus high grade immune checkpoint inhibitor therapy-related pneumonitis
Antonious Hazim, Jacob Shreve, Irene Riestra Guiance, Damian McGlothlin, Gordon Ruan, Keith Mcconn, Robert Haemmerle, Konstantinos Leventakos, Ashley Egan, Svetomir Markovic

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1402; DOI: 10.1136/jitc-2023-SITC2023.1266
1268 Eruptive keratoacanthomas secondary to nivolumab therapy
Eric Olsen, Steven Svoboda, Marjorie Montanez-Wiscovich, Sami Saikaly

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1403; DOI: 10.1136/jitc-2023-SITC2023.1268

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages